Webinar List
Lung cancer is the deadliest cancer worldwide and the most common cancer in Asia. In fact, 59% of all lung cancer cases occurs in Asia and around 21% of all cancer related deaths in Asia are lung cancer-related.
The treatment of lung cancer is evolving rapidly, and current evidences are beginning to show that new approaches for thoracic procedures & treatments have excellent outcomes towards the quality of life.
However, `Lobectomy` is still the fundamental procedure at this moment. Hence, to improve this technique would greatly improve patient outcomes.
In this webinar, three top experts from Asia Pacific shared their technique, strategy and insights for VATS lobectomy from various aspect.
In this webinar, we bring a global perspective that will challenge the current Gold Standard of treatment. Dr. Watanabe from Japan, will share the results of JCOG0802 which have been recently reported on AATS. Dr. Harvey Pass of the U.S. will share the design of CALGB140503, the results of which will be released next year, and Dr. Fang from China, will moderate the discussion following the presentations.
Will these two studies change the future of treatment of lung cancer and challenge the Gold Standard?
In addition, we will have a panel discussion on the strategy for the treatment of early lung cancer, with a broad overview on how these changes might impact patients, surgical care teams and surgical societies. This discussion will be focusing on these new studies, the evidence generated and the experts' views on it.
This session is moderated by Dr. Anand Shastri, Thoracic Surgeon and the Senior Director, Medical and Clinical Affairs for Johnson and Johnson India, and for Ethicon, Asia Pacific.
The medical devices mentioned in this presentation are for illustrative purpose only. Not all products are licensed or available in all Asia Pacific and EMEA countries. This publication is not intended for distribution outside of the Asia Pacific and EMEA region. The third-party trademarks used herein are the trademarks of the respective owners.
213111-220510
販売名：パワードエシェロンフレックス７ 認証番号：227AABZX00087000
販売名：パワードエシェロンフレックス７カートリッジ 承認番号：22700BZX00290000
販売名：ＧＳＴカートリッジ 承認番号：22700BZX00155000
販売名：エンドスコピック パワード リニヤー カッター 認証番号：22500BZX00396000
販売名：バイクリル 承認番号：15700BZY01341000
Lung cancer is the deadliest cancer worldwide and the most common cancer in Asia. In fact, 59% of all lung cancer cases occur in Asia and furthermore, 21% of all cancer related deaths in Asia are because of lung cancer. In addition, approximately one third of all lung cancer patients in East Asia are non-smokers. The treatment of lung cancer is evolving rapidly, and current evidence is beginning to show that new approaches for thoracic procedures and treatments have excellent outcomes and quality of life related results. Advances in diagnostic methods, earlier diagnosis and the important requirement of preserving as much lung function as possible, have made lung cancer surgery evolve to become as Minimally Invasive as possible and hence, has led to the widespread adoption of VATS and Uniportal VATS in Asia. In addition, lung function preserving operations such as segmentectomy and sub lobar radical resections also have a high interest in Asia Pacific and are being adopted as a new procedure strategy.
There are two big studies that are being conducted in Japan (JCOG0802) and in the US(CALGB140503), on the oncological outcomes of VATS segmentectomy and its comparison with the more traditional VATS lobectomy. This is the first episode of our exciting series of two live webinars, where thoracic experts from Asia Pacific will share their clinical experiences, and practical techniques on VATS segmentectomy. This discussion on surgical methods, pros and cons will be underpinned with the latest evidence available.
The medical devices mentioned in this presentation are for illustrative purpose only. Not all products are licensed or available in all Asia Pacific and EMEA countries. This publication is not intended for distribution outside of the Asia Pacific and EMEA region. The third-party trademarks used herein are the trademarks of the respective owners.
213079-220510
販売名：エンドパス エンドカッター ＥＣ４５ 承認番号：22100BZX00089000
販売名：エンドカッター 承認番号：21900BZX00881000
販売名：パワードエシェロンフレックス７ 認証番号：227AABZX00087000
販売名：パワードエシェロンフレックス７カートリッジ 承認番号：22700BZX00290000
販売名：ＧＳＴカートリッジ 承認番号：22700BZX00155000
There is only one straight access from the utility port to the target structure, and this straight access should be reserved for operator's right hand, to ensure the maximum degree of freedom and safety. For any experienced single port surgeon, the best instrument setting will be Harmonic HD1000i in operator’s right hand for sharp dissection, and long curved sucker in operator’s left hand for suction/traction/blunt dissection. Find out more on the key points of the surgical procedure of single port VATS lobectomy with Dr Liu Chia-Chuan.
219859-220706